A PYMNTS Company

US: Sanofi seeks billions in EpiPen antitrust suit

By  |  August 13, 2019

Sanofi wants Mylan to pay up to US$11.7 billion in damages for engaging in a scheme to squelch competition to its EpiPen allergy treatment, which became the center of a firestorm over drug price increases.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The French drugmaker detailed its damages claim on Friday, August 9, as it urged a federal judge in Kansas City, Kansas, to allow it to proceed with a lawsuit alleging Mylan took actions to crush the competitive threat posed by Sanofi’s newer product, Auvi-Q.

    In the suit filed in Trenton, New Jersey, Sanofi claimed Mylan caused it to lose hundreds of millions of dollars in sales by erecting barriers to US consumers’ access to and use of a rival product, Auvi-Q.

    In particular, Sanofi claimed Mylan offered rebates to insurers, pharmaceutical benefit managers, and state Medicaid agencies conditioned on Auvi-Q not being an epinephrine auto-injector device they would reimburse for use by consumers.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.